For research use only. Not for therapeutic Use.
S19-1035 is a highly potent and specific aldo-keto reductase 1C3 (AKR1C3) inhibitor. S19-1035 inhibits AKR1C3 with an IC50 value of 3.04 nM. S19-1035 can be used for the research of tumor[1].
S19-1035 exhibits inhibitory activity for AKR1C3 with an IC50 value of 3.04 nM[1].
S19-1035 (0-100 μM; 72 h or 96 h) has less cytotoxic and had limited antitumor effects when used alone[1].
S19-1035 (10 μM; 8 days) significantly reversed the doxorubicin (DOX) resistance in a resistant breast cancer cell line in co-administration[1].
| Catalog Number | I042357 |
| CAS Number | 2986319-18-8 |
| Synonyms | N-(2-chlorophenyl)-2-[(3,5-dimethyl-1,2-oxazol-4-yl)methoxy]benzamide |
| Molecular Formula | C19H17ClN2O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H17ClN2O3/c1-12-15(13(2)25-22-12)11-24-18-10-6-3-7-14(18)19(23)21-17-9-5-4-8-16(17)20/h3-10H,11H2,1-2H3,(H,21,23) |
| InChIKey | DPKPKQOCNMAUHN-UHFFFAOYSA-N |
| SMILES | CC1=C(C(=NO1)C)COC2=CC=CC=C2C(=O)NC3=CC=CC=C3Cl |
| Reference | [1]. Yang Liu, et al. Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer. Eur J Med Chem. 2022 Dec 13;247:115013. |
